Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia

Diabetes Care

Volumn 35, Issue 12, 2012, Pages 2631-2639

  Satoh Asahara, Noriko ^a   Shimatsu, Akira ^a   Sasaki, Yousuke ^a   Nakaoka, Hidenori ^a   Himeno, Akihiro ^a   Tochiya, Mayu ^a   Kono, Shigeo ^a   Takaya, Tomohide ^a   Ono, Koh ^b   Wada, Hiromichi ^a   Suganami, Takayoshi ^c   Hasegawa, Koji ^a   Ogawa, Yoshihiro ^c  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OBESITY; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULSE WAVE; RISK REDUCTION;

DYSLIPIDEMIAS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OBESITY;

EID: 84869780896     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0269     Document Type: Article

References (40)

1. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AWJr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808 (Pubitemid 38063703)
2. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005;25:2062-2068 (Pubitemid 41416301)
3. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964 (Pubitemid 41746764)
4. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-184 (Pubitemid 46048464)
5. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008;57:3239-3246
6. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007;447:1116-1120 (Pubitemid 47014427)
7. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1424-432
8. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophageswith anti-inflammatory properties. Cell Metab 2007;6:137-143 (Pubitemid 47189091)
9. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004;110:1564-1571 (Pubitemid 39297977)
10. Satoh N, Shimatsu A, Himeno A, et al. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010;33:e7
11. Fujisaka S, Usui I, Bukhari A, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009;58:2574-2582
12. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757 (Pubitemid 35364932)
13. Yokoyama M, Origasa H, Matsuzaki M, et al.; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-1098 (Pubitemid 46483662)
14. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007;30:144-146 (Pubitemid 46061295)
15. Itoh M, Suganami T, Satoh N, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007;27:1918-1925 (Pubitemid 47315642)
16. Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 2009;32:1004-1008
17. Yamada H, Yoshida M, Nakano Y, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol 2008;28:2173-2179
18. Renier G, Skamene E, DeSanctis J, Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities. Arterioscler Thromb 1993;13:1515-1524 (Pubitemid 23303406)
19. Michaud SE, Renier G. Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes 2001;50:660-666 (Pubitemid 32195233)
20. Calder PC. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 2009;91:791-795
21. Ueeda M, Doumei T, Takaya Y, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008;72:1836-1843
22. Matsuzaki M, Yokoyama M, Saito Y, et al.; JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009;73:1283-1290
23. Satoh N, Shimatsu A, Kato Y, et al. Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. Hypertens Res 2008;31:1921-1930
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Expert Panel on detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
25. Saito Y, Yokoyama M, Origasa H, et al.; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200:135-140
26. International clinical harmonization of hemoglobin A1c in Japan: From JDS to NGSP values. The report from "The Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing"of Japan Diabetes Society (JDS) [article online], 2012. Available from http://www.jds.or.jp/jds-or-jp0/ uploads/photos/813.pdf. Accessed 4 February 2012
27. Manigrasso MR, Ferroni P, Santilli F, et al. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab 2005;90:5876-5879 (Pubitemid 41415505)
28. Esposito K, Pontillo A, Giugliano F, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003;88:1055-1058 (Pubitemid 36337756)
29. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell 2010;142:687-698
30. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet 2011;20:790-805
31. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-2853 (Pubitemid 30029809)
32. Namiki M, Kawashima S, Yamashita T, et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004;172:21-29 (Pubitemid 38058597)
33. Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010;24:2869-2880
34. Kawashima A,Harada T, Imada K, Yano T, Mizuguchi K. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids 2008;79:59-65
35. Thompson PW, Bayliffe AI, Warren AP, Lamb JR. Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine 2007;39:184-191 (Pubitemid 47610737)
36. Matsumoto M, Sata M, Fukuda D, et al. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2008;197:524-533 (Pubitemid 351417875)
37. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARg-dependent manner in human adipocytes. Obesity (Silver Spring) 2011;19:262-268
38. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-2049 (Pubitemid 38620209)
39. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153-6160
40. Lee SH, Shin MJ, Kim JS, et al. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarctionddata from Infarction Prognosis Study (IPS) Registry. Circ J 2009;73:2250-2257